Altre lingue Enliven Therapeutics, Inc.

Azioni

ELVN

US29337E1029

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 27/06/2024			Variaz. 5gg	Var. 1 gen.
23,45 ^USD	+10,72%		+11,45%	+69,44%

27/06	Un insider di Enliven Therapeutics ha venduto azioni per un valore di 259.902 dollari, secondo un recente deposito SEC	MT
11/06	ENLIVEN THERAPEUTICS, INC. : prospettiva positiva di Baird	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Enliven Therapeutics Insider Sold Shares Worth $259,902, According to a Recent SEC Filing	27/06
Enliven Therapeutics, Inc.(NasdaqGS:ELVN) added to S&P Pharmaceuticals Select Industry Index	24/06
Enliven Therapeutics, Inc. Appoints Lori Kunkel to the Committee	29/05
Enliven Therapeutics to Present at Two Upcoming Investor Conferences	29/05
Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing	20/05
Enliven Therapeutics Q1 Loss Narrows	14/05
Enliven Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update	14/05
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	11/04
Enliven Therapeutics, Inc. Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia	11/04
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors	09/04
Enliven Therapeutics, Inc. Appoints Lori Kunkel to Board of Directors	09/04
Enliven Therapeutics, Inc. announced that it has received $90.000014 million in funding	03/04
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024	28/03
North American Morning Briefing : Investors -2-	21/03
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates	19/03
Enliven Therapeutics, Inc. announced that it expects to receive $90.000014 million in funding	19/03
Enliven Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	14/03
Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Enliven Therapeutics, Inc.

Azioni

ELVN

US29337E1029

Altre lingue

Filtri